Log in

AtriCure Stock Forecast, Price & News

+0.10 (+0.25 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $39.99
50-Day Range
MA: $41.73
52-Week Range
Now: $39.99
Volume782,641 shs
Average Volume415,230 shs
Market Capitalization$1.80 billion
P/E RatioN/A
Dividend YieldN/A
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Read More
AtriCure logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:ATRC



Sales & Book Value

Annual Sales$230.81 million
Book Value$6.25 per share


Net Income$-35,190,000.00


Market Cap$1.80 billion
Next Earnings Date11/4/2020 (Estimated)
+0.10 (+0.25 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

How has AtriCure's stock been impacted by Coronavirus (COVID-19)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC stock has increased by 13.4% and is now trading at $39.99.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of AtriCure?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AtriCure

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for AtriCure

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Tuesday, July, 28th. The medical device company reported ($0.38) EPS for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.21. The medical device company had revenue of $40.82 million for the quarter, compared to the consensus estimate of $36.07 million. AtriCure had a negative net margin of 23.64% and a negative return on equity of 19.55%. The company's revenue for the quarter was down 30.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.17) earnings per share.
View AtriCure's earnings history

What price target have analysts set for ATRC?

7 brokerages have issued twelve-month price targets for AtriCure's stock. Their forecasts range from $45.00 to $60.00. On average, they expect AtriCure's share price to reach $52.71 in the next year. This suggests a possible upside of 31.8% from the stock's current price.
View analysts' price targets for AtriCure

Are investors shorting AtriCure?

AtriCure saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,070,000 shares, an increase of 15.0% from the August 15th total of 1,800,000 shares. Based on an average trading volume of 314,200 shares, the short-interest ratio is currently 6.6 days.
View AtriCure's Short Interest

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Who are AtriCure's key executives?

AtriCure's management team includes the following people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (10.61%), Vanguard Group Inc. (5.05%), Orbimed Advisors LLC (2.73%), TimesSquare Capital Management LLC (2.62%), Gilder Gagnon Howe & Co. LLC (2.30%) and GW&K Investment Management LLC (1.92%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves.
View institutional ownership trends for AtriCure

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, GW&K Investment Management LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Neuberger Berman Group LLC, Peregrine Capital Management LLC, Silvercrest Asset Management Group LLC, Nuveen Asset Management LLC, and Bank of New York Mellon Corp. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel, and Regina E Groves.
View insider buying and selling activity for AtriCure

Which institutional investors are buying AtriCure stock?

ATRC stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, TimesSquare Capital Management LLC, Gilder Gagnon Howe & Co. LLC, Orbimed Advisors LLC, Perceptive Advisors LLC, Vanguard Group Inc., Man Group plc, and Driehaus Capital Management LLC.
View insider buying and selling activity for AtriCure

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $39.99.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.80 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 620 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is www.atricure.com.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.